The Mayo Clinic will soon debut a major, comprehensive strategy to combat diabetes, sources say. Details are vague but Mayo officials have told local biotech officials that a big initiative is in the works, which could include research, education, outreach, ways to speed technology transfer, or all of the above. Already, the pieces are falling into place.
Mayo, in partnership with McGill University, recently launched a Phase II clinical trial of a promising Type I diabetes drug developed by Exsulin Corp. of Burnsville.
MedCity News by Thomas Lee, 1/6/10